Curve Founder: The potential risks of over-collateralized stablecoins may come from government regulation
Decentralized lending platform Curve Finance founder Michael Egorov believes that the potential risks of over-collateralized stablecoins are not necessarily the reserve-related risks commonly noticed by investors, but geopolitical risks brought about by government regulation. In an interview, Egorov stated that underlying assets supporting collateralized stablecoins, including cash deposits from financial institutions and U.S. Treasury bonds and other government securities, are easily affected by asset freezes and seizures.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.